Celularity Inc. CELU

Company Overview

Celularity Inc. is a U.S.-based biotechnology company focused on the development of placental-derived allogeneic cell therapies, biomaterial products, and regenerative medicine technologies. The company operates primarily in the biotechnology, cellular therapeutics, and advanced biomaterials industries. Celularity’s core strategy centers on leveraging postpartum human placental tissue as a source for cellular therapies intended for oncology, infectious disease, degenerative conditions, and tissue repair applications. The company also develops and commercializes biomaterial products used in wound care, surgical applications, and regenerative medicine.

The company’s principal business lines include its Cell Therapy platform, which develops allogeneic natural killer (NK) cell, T-cell, and mesenchymal-like adherent stromal cell therapies, and its Biomaterial Products business, which markets placental-derived products for wound management and surgical use. Revenue has historically been derived from commercial biomaterial products, licensing arrangements, and collaborative activities, while its therapeutic pipeline remains in various stages of clinical development. Celularity originated from assets associated with Celgene and was later established as an independent entity before becoming publicly traded through a merger with a special purpose acquisition company in 2021.

Business Operations

Celularity organizes its operations around cellular therapeutics and regenerative biomaterials. Its Cell Therapy programs include investigational therapies such as placental-derived NK cells and genetically modified CAR-NK candidates targeting hematologic malignancies and solid tumors. The company also develops placental-derived T-cell therapies and other immune-modulating cellular platforms. In parallel, its Biomaterial Products segment commercializes products derived from human placental tissue for use in wound care, burns, tendon repair, and surgical applications. These products have historically represented a meaningful source of commercial revenue relative to the company’s clinical-stage therapeutic programs.

The company operates primarily in the United States but maintains collaborative and supply relationships with external manufacturers, clinical institutions, and research organizations. Celularity controls proprietary placental sourcing, processing, and cryopreservation technologies intended to support scalable allogeneic manufacturing. The company has disclosed strategic collaborations and licensing relationships involving cell therapy development and manufacturing capabilities, including relationships connected to former Celgene-affiliated scientific programs. Public filings also identify subsidiaries supporting research, product commercialization, and intellectual property management activities.

Strategic Position & Investments

Celularity’s strategic direction has focused on advancing off-the-shelf allogeneic cell therapies while expanding commercial regenerative medicine products. The company has emphasized the potential scalability and availability advantages of placental-derived cells compared with autologous approaches. Management has publicly identified oncology, immunology, and regenerative medicine as long-term growth areas, with investment directed toward clinical trials, manufacturing infrastructure, and platform development.

The company has pursued investments in manufacturing capabilities and intellectual property tied to placental-derived therapeutic platforms. Celularity has also explored partnerships intended to accelerate development of CAR-NK technologies and other engineered immune cell programs. Its portfolio includes subsidiaries and operating units associated with placental biomaterials and cell therapy research. Public disclosures indicate ongoing involvement in emerging sectors such as cellular immunotherapy, regenerative medicine, and bioengineered tissue applications, although commercialization of several pipeline programs remains dependent on clinical and regulatory progress.

Geographic Footprint

Celularity is headquartered in Florham Park, New Jersey, and its principal operations are concentrated in the United States. The company conducts research, development, manufacturing, and commercial activities primarily through U.S.-based facilities and partnerships. Its biomaterial products are marketed mainly within the domestic healthcare market, including hospitals, surgical centers, and wound care providers.

While the company’s operational footprint is primarily North American, Celularity has indicated broader strategic ambitions involving international partnerships, licensing opportunities, and potential future commercialization in additional markets. The company’s clinical and scientific collaborations have included relationships with institutions and partners in multiple regions, though publicly available disclosures indicate that the majority of operational infrastructure and revenue generation remain U.S.-focused.

Leadership & Governance

Celularity was founded with scientific and commercial roots connected to former Celgene leadership and regenerative medicine initiatives. The company has emphasized a strategy combining cellular immunotherapy innovation with commercial biomaterial products to create diversified biotechnology operations. Leadership communications and public filings have consistently highlighted scalable allogeneic therapies and placental-derived technologies as central to long-term corporate strategy.

Key executives and leadership figures include:

• Robert J. Hariri – Founder and Former Chief Executive Officer
• Dr. Robert J. Hariri – Chair and Executive leadership roles associated with strategic scientific direction
• Matthew P. Schissler – Former Chief Executive Officer and Executive Chair
• Vimal Mehta – Former President and business development executive
• Mark Augustine – Former Chief Financial Officer
• Laura Sepp-Lorenzino – Former scientific and research leadership executive

Information regarding executive roles and leadership composition has changed periodically through restructurings and management transitions disclosed in public filings. Current executive and board appointments should be confirmed through the company’s most recent SEC filings, including annual reports and proxy statements.